MNPR Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About MNPR Interactive Breakdown Better Bets vs. MNPR Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Clinical Pipeline Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    Monopar Therapeutics (MNPR)

    Market Price (9/26/2026): $85.37 | Market Cap: $729.3 MilSector: Health Care | Industry: Biotechnology

    Monopar Therapeutics (MNPR)

    Market Price (9/26/2026): $85.37
    Market Cap: $729.3 Mil
    Sector: Health Care
    Industry: Biotechnology

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18%

    Megatrend and thematic drivers
    Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more.

    Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -22 Mil

    Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.5%

    Key risks
    MNPR key risks include [1] a history of clinical trial failure with its Validive program and [2] significant competitive threats to its lead asset, Show more.

    0 Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18%
    1 Megatrend and thematic drivers
    Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more.
    2 Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
    3 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -22 Mil
    4 Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.5%
    5 Key risks
    MNPR key risks include [1] a history of clinical trial failure with its Validive program and [2] significant competitive threats to its lead asset, Show more.

    MNPR in ETFs

    Weight = MNPR's share of each fund

    VTI0.00%
    ITOT0.00%
    IWM0.01%
    VTWO0.02%
    IWO0.01%
    IWN0.00%
    IWV0.00%

    Valuation & Metrics

    FYE: 12/31MNPR [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$0.0 Mil—
    FY 2026 Sales$0.4 Mil—
    FY 2027 Sales$27.9 Mil—
    FY 2026 Sales Growth——
    FY 2027 Sales Growth6,875.7%12.8%
    EARNINGS
    LTM Net Income (GAAP) [3]$-17.8 Mil—
    FY 2026 Net Income (Non-GAAP)$-23.1 Mil—
    FY 2027 Net Income (Non-GAAP)$-19.0 Mil—
    FY 2027 Net Income Growth—18.0%
    FY 2026 EPS (Non-GAAP)$-2.90—
    FY 2027 EPS (Non-GAAP)$-2.46—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S1,823.21.6
    FY 2027 P/S26.1—
    FY 2026 P/E—7.7
    FY 2027 P/E——

    [1] MNPR forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 9/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    null

    AI Analysis | Feedback

    MetricValueDateSource
    Active Clinical Trials510282025Link
    Lead Product Candidate in Phase 2b/3Validive3092022Link
    Product Candidate in Phase 1bCamsirubicin7112023Link
    Product Candidate in Phase 1MNPR-101-Zr6112025Link
    Product Candidate in Phase 1aMNPR-101-Lu6112025Link
    Total Patent Families269042025Link
    Granted Patents179042025Link
    Pending Patents99042025Link
    Number of Employees1611072025Link
    Number of Collaborations46112024Link

    Price Chart

    null
    Upcoming
    11/12/2026Earnings ReleaseRev: -
    EPS: -

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 9/25/2026

    Monopar Therapeutics (MNPR) stock has gained about 30% since 5/31/2026 because of the following key factors:

    1. Advancement of ALXN1840 Towards Regulatory Approval. Monopar Therapeutics initiated a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for ALXN1840, its lead candidate for Wilson Disease, on July 22, 2026. This significant regulatory milestone was further supported by the FDA granting Rare Pediatric Disease (RPD) designation to ALXN1840 on June 30, 2026.

    2. Consistent Positive Clinical Trial Data for ALXN1840. Throughout this period, Monopar reported favorable data for ALXN1840. This included the publication of Phase 2 study results in May 2026, demonstrating improved copper balance in Wilson Disease patients. Further presentations in May and June 2026 highlighted Phase 2 data showing liver disease stabilization and neurological improvement, alongside Phase 3 data indicating greater neurological and global clinical benefits compared to standard of care.

    Show more
    Updated on 9/25/2026

    Monopar Therapeutics (MNPR) stock has gained about 30% since 5/31/2026 because of the following key factors:

    1. Advancement of ALXN1840 Towards Regulatory Approval. Monopar Therapeutics initiated a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for ALXN1840, its lead candidate for Wilson Disease, on July 22, 2026. This significant regulatory milestone was further supported by the FDA granting Rare Pediatric Disease (RPD) designation to ALXN1840 on June 30, 2026.

    2. Consistent Positive Clinical Trial Data for ALXN1840. Throughout this period, Monopar reported favorable data for ALXN1840. This included the publication of Phase 2 study results in May 2026, demonstrating improved copper balance in Wilson Disease patients. Further presentations in May and June 2026 highlighted Phase 2 data showing liver disease stabilization and neurological improvement, alongside Phase 3 data indicating greater neurological and global clinical benefits compared to standard of care.

    3. Positive Analyst Sentiment and Upgraded Price Targets. As of September 22, 2026, Monopar Therapeutics held a consensus "Strong Buy" rating from 13 analysts, with an average price target of $127.62. This target represented a 43.65% potential upside from the stock's price at that time, reflecting strong confidence in the company's prospects.

    4. Better-Than-Expected Fiscal Q2 2026 Financial Results. For fiscal Q2 2026, which ended June 30, 2026, Monopar reported a net loss of $0.62 per share, surpassing the consensus analyst estimate of a $0.6335 loss by approximately 2.13%. This narrower-than-anticipated loss, in the absence of revenue for the clinical-stage company, suggested effective expense management.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The 31.1% change in MNPR stock from 5/31/2026 to 9/25/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
    (LTM values as of)53120269252026Change
    Stock Price ($)65.0485.2331.1%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)99-0.1%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    5/31/2026 to 9/25/2026
    ReturnCorrelation
    MNPR31.1% 
    Market (SPY)2.2%17.0%
    Sector (XLV)14.7%15.5%

    Fundamental Drivers

    The 55.5% change in MNPR stock from 2/28/2026 to 9/25/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
    (LTM values as of)22820269252026Change
    Stock Price ($)54.8085.2355.5%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)79-16.6%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    2/28/2026 to 9/25/2026
    ReturnCorrelation
    MNPR55.5% 
    Market (SPY)13.0%30.4%
    Sector (XLV)7.5%17.5%

    Fundamental Drivers

    The 149.6% change in MNPR stock from 8/31/2025 to 9/25/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
    (LTM values as of)83120259252026Change
    Stock Price ($)34.1585.23149.6%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)79-18.1%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    8/31/2025 to 9/25/2026
    ReturnCorrelation
    MNPR149.6% 
    Market (SPY)20.9%25.5%
    Sector (XLV)26.4%16.7%

    Fundamental Drivers

    The 2538.9% change in MNPR stock from 8/31/2023 to 9/25/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
    (LTM values as of)83120239252026Change
    Stock Price ($)3.2385.232538.9%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)39-68.6%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    8/31/2023 to 9/25/2026
    ReturnCorrelation
    MNPR2538.9% 
    Market (SPY)77.8%6.8%
    Sector (XLV)34.7%1.0%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    MNPR Return-48%-26%-86%1193%197%36%190%
    Peers Return-7%32%41%-1%13%-2%88%
    S&P 500 Return27%-19%24%23%16%13%105%

    Monthly Win Rates [3]
    MNPR Win Rate17%33%17%42%67%44% 
    Peers Win Rate42%67%58%50%83%38% 
    S&P 500 Win Rate75%42%67%75%67%56% 

    Max Drawdowns [4]
    MNPR Max Drawdown-70%-60%-92%-67%-46%-33% 
    Peers Max Drawdown-27%-19%-12%-23%-29%-15% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: VRTX, APMD, ATTO, BLSM, BRVE.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 9/25/2026 (YTD)

    How Low Can It Go

    EventMNPRS&P 500
    2025 US Tariff Shock
      % Loss-37.0%-18.8%
      % Gain to Breakeven58.8%23.1%
      Time to Breakeven10 days79 days
    2024 Yen Carry Trade Unwind
      % Loss-37.2%-7.8%
      % Gain to Breakeven59.3%8.5%
      Time to Breakeven34 days18 days
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-60.4%-9.5%
      % Gain to Breakeven152.7%10.5%
      Time to Breakeven94 days24 days
    2023 SVB Regional Banking Crisis
      % Loss-78.7%-6.7%
      % Gain to Breakeven369.2%7.1%
      Time to Breakeven472 days31 days
    2022 Inflation Shock & Fed Tightening
      % Loss-57.1%-24.5%
      % Gain to Breakeven132.9%32.4%
      Time to Breakeven46 days427 days
    2020 COVID-19 Crash
      % Loss-54.6%-33.7%
      % Gain to Breakeven120.4%50.9%
      Time to Breakeven2010 days140 days

    Compare to VRTX, APMD, ATTO, BLSM, BRVE

    In The Past

    Monopar Therapeutics's stock fell -37.0% during the 2025 US Tariff Shock. Such a loss loss requires a 58.8% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    EventMNPRS&P 500
    2025 US Tariff Shock
      % Loss-37.0%-18.8%
      % Gain to Breakeven58.8%23.1%
      Time to Breakeven10 days79 days
    2024 Yen Carry Trade Unwind
      % Loss-37.2%-7.8%
      % Gain to Breakeven59.3%8.5%
      Time to Breakeven34 days18 days
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-60.4%-9.5%
      % Gain to Breakeven152.7%10.5%
      Time to Breakeven94 days24 days
    2023 SVB Regional Banking Crisis
      % Loss-78.7%-6.7%
      % Gain to Breakeven369.2%7.1%
      Time to Breakeven472 days31 days
    2022 Inflation Shock & Fed Tightening
      % Loss-57.1%-24.5%
      % Gain to Breakeven132.9%32.4%
      Time to Breakeven46 days427 days
    2020 COVID-19 Crash
      % Loss-54.6%-33.7%
      % Gain to Breakeven120.4%50.9%
      Time to Breakeven2010 days140 days

    Compare to VRTX, APMD, ATTO, BLSM, BRVE

    In The Past

    Monopar Therapeutics's stock fell -37.0% during the 2025 US Tariff Shock. Such a loss loss requires a 58.8% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About Monopar Therapeutics (MNPR)

    Monopar Therapeutics Inc. (MNPR) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of cancer. Its most advanced product candidate is Validive, a clonidine hydrochloride mucobuccal tablet currently in Phase 2b/3 clinical trials. Validive aims to prevent severe oral mucositis, a debilitating side effect, in patients with oropharyngeal cancer undergoing chemoradiotherapy.

    The company's pipeline extends to several other promising drug candidates. Camsirubicin, an analog of doxorubicin, is in Phase 1b development for advanced soft tissue sarcoma. Monopar is also developing MNPR-101, a targeted antibody for various cancers, and MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101, which targets both cancer and severe COVID-19. Furthermore, MNPR-202 is an analog of camsirubicin being developed to potentially treat cancers resistant to current therapies. Monopar Therapeutics primarily serves the oncology market, addressing critical unmet needs for cancer patients, and is also exploring an application in severe COVID-19.

    AI Analysis | Feedback

    • It's like an early-stage Genentech, but specialized in developing several new cancer and supportive care therapies.
    • Think of it as a small, independent version of the oncology R&D division of a major pharmaceutical company like Pfizer or Merck.

    AI Analysis | Feedback

    • Validive: A clonidine hydrochloride mucobuccal tablet in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients.
    • Camsirubicin: An analog of doxorubicin in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma.
    • MNPR-101: A urokinase plasminogen activator receptor targeted antibody developed for the treatment of various cancers.
    • MNPR-101 RIT: A radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19.
    • MNPR-202: An analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.

    AI Analysis | Feedback

    As a clinical-stage biopharmaceutical company, Monopar Therapeutics Inc. (MNPR) is engaged in the research and development of therapeutic product candidates. Its lead candidates are currently in Phase 1b or Phase 2b/3 clinical trials. Therefore, Monopar Therapeutics does not currently have major customers for its therapeutic products, as these products are still under development and have not yet been approved for commercial sale to other companies or individual patients.

    AI Analysis | Feedback

    • NorthStar Medical Radioisotopes, LLC

    AI Analysis | Feedback

    Chandler D. Robinson, MD MBA MSc – Co-Founder, Chief Executive Officer and Board Member

    Dr. Robinson co-founded Monopar Therapeutics and has served as its CEO since its inception in 2014. He previously co-founded and was CEO of Tactic Pharma, where he led the successful sale of its lead compound. He was also a co-founder and board member of Wilson Therapeutics, which was acquired by Alexion (now AstraZeneca). His prior experiences include working in the Nexavar marketing division at Onyx Pharmaceuticals, co-managing a healthcare clinic, and working at Bear Stearns investment bank. Dr. Robinson founded and presides over an undergraduate research-focused non-profit. A compound he researched as an undergraduate at Northwestern University, and published on in Science, completed a Phase III clinical trial for Wilson Disease and is now being advanced to an NDA filing at Monopar.

    Quan Vu – Chief Financial Officer

    Mr. Vu was appointed Chief Financial Officer of Monopar Therapeutics effective March 3, 2025. He brings over 20 years of experience in corporate and financial strategy, investment banking, and public company management. Mr. Vu has served as a Venture Partner at ZhongMei Capital, an investment firm focused on early-stage biopharmaceutical companies. His previous roles include Chief Financial Officer and Chief Business Officer at Ocugen, Inc., and Chief Operating Officer and Chief Business Officer for 180 Life Sciences Corp. He also provided consulting services through his firm, Melius BioPharma Consulting, and held leadership positions at Opiant Pharmaceuticals, Inc., Impax Laboratories, Inc., Elevance Health, Inc. (formerly Anthem, Inc.), and Amgen, Inc. His early career involved work in healthcare corporate finance and mergers & acquisitions at Morgan Stanley and Goldman Sachs.

    Andrew Cittadine, MBA – Chief Operating Officer

    Mr. Cittadine provides leadership and oversight of global operations and business development strategy, leveraging his background in building and selling healthcare businesses. He received his BA, BS, and MS from Stanford and an MBA from Northwestern's Kellogg School of Management.

    Andrew P. Mazar, PhD – Co-Founder & EVP, Research & Development

    Dr. Mazar is a co-founder of Monopar Therapeutics.

    Christopher M. Starr – Co-Founder and Executive Chairman of the Board

    Mr. Starr is a co-founder of Monopar Therapeutics and serves as the Executive Chairman of the Board.

    AI Analysis | Feedback

    Key Risks to Monopar Therapeutics (MNPR)

    1. Clinical Trial Failure and Inability to Obtain Regulatory Approval: As a clinical-stage biopharmaceutical company, Monopar Therapeutics' business prospects are fundamentally tied to the successful outcome of its ongoing and future clinical trials for product candidates such as Validive (in Phase 2b/3), Camsirubicin (in Phase 1b), MNPR-101, MNPR-101 RIT, and MNPR-202. Biopharmaceutical drug development inherently involves a high risk of failure at various stages of clinical trials due to lack of efficacy, safety concerns, or unforeseen side effects. Furthermore, even with successful trial data, there is no guarantee that regulatory bodies, such as the FDA, will grant marketing approval. The failure of any of its lead product candidates to successfully complete trials or receive regulatory approval would prevent Monopar from commercializing its therapies and generating revenue, which would significantly impact its viability.
    2. Dependence on External Funding: Monopar Therapeutics currently has no revenue-generating commercialized products and is engaged in costly research and development activities, particularly advanced clinical trials. The company's continued operations and its ability to advance its pipeline are heavily reliant on its capacity to raise substantial additional capital through equity offerings, debt financing, or strategic partnerships. Failure to secure adequate and timely funding could lead to delays, suspension, or termination of its critical development programs, thereby threatening the company's long-term sustainability.
    3. Competition and Market Acceptance: Should Monopar's product candidates successfully complete clinical trials and receive regulatory approval, they will enter highly competitive markets for the treatment of cancer and severe COVID-19. They will face competition from existing therapies, including established drugs and generic alternatives, as well as new treatments being developed by larger, more established biopharmaceutical companies. The ability to achieve significant market acceptance, establish competitive pricing, and secure favorable reimbursement will be crucial for commercial success, and there is a risk that Monopar's products may not achieve sufficient market share or pricing power to generate substantial revenue.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Monopar Therapeutics (MNPR) operates in several distinct therapeutic areas with the following addressable market sizes:

    • Validive (for chemoradiotherapy induced severe oral mucositis): The global market for chemotherapy-induced oral mucositis is anticipated to grow from USD 1.35 billion in 2025 to USD 2.20 billion in 2035, exhibiting a compound annual growth rate (CAGR) of 5.3%.
    • Camsirubicin (for advanced soft tissue sarcoma): The soft tissue sarcoma market across the top 7 major markets (United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan) was valued at USD 2.8 billion in 2024 and is projected to reach USD 5.0 billion by 2035, growing at a CAGR of 5.10%. The global soft tissue sarcoma treatment market size was valued at USD 1,455.12 million in 2024 and is projected to grow to USD 3,910.15 million by 2034, with a CAGR of 10.4%.
    • MNPR-101 (urokinase plasminogen activator receptor targeted antibody for various cancers): The global urokinase market size was valued at USD 1.8 billion in 2023 and is projected to reach USD 3.1 billion by 2033, growing at a CAGR of 5.7%. Urokinase-type plasminogen activator receptor (uPAR) is identified as an attractive target for cancer therapies. The global market for Urokinase was estimated at US$1.8 billion in 2024 and is expected to reach US$2.4 billion by 2030, with a CAGR of 4.6%.
    • MNPR-101 RIT (radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer): The global radioimmunotherapy market size was estimated at USD 2.68 billion in 2024 and is predicted to surpass approximately USD 12.70 billion by 2034, growing at a CAGR of 16.83%. North America accounts for approximately 45% of the global share.
    • MNPR-202 (analog of camsirubicin to potentially treat doxorubicin- and camsirubicin-resistant cancers): The global doxorubicin market was valued at USD 1.8 billion in 2024 and is projected to reach USD 2.6 billion by 2032, with a CAGR of 4.7%. Another estimate indicates the global doxorubicin market size was valued at USD 1.06 billion in 2024 and is projected to grow from USD 1.14 billion in 2025 to reach USD 1.76 billion by 2033, exhibiting a CAGR of 5.6%.

    AI Analysis | Feedback

    For Monopar Therapeutics (MNPR), the expected drivers of future revenue growth over the next 2-3 years are primarily centered on the progression and potential commercialization of its refocused pipeline, particularly its radiopharmaceutical programs and the recently acquired asset for Wilson Disease.

    1. Potential FDA Approval and Commercialization of ALXN1840 for Wilson Disease: Monopar Therapeutics assumed full responsibility for the investigational new drug (IND) application for ALXN1840, a treatment for Wilson Disease, from Alexion Pharmaceuticals in June 2025. The company is preparing to submit a New Drug Application (NDA) to the FDA in early 2026. Successful regulatory approval and subsequent commercial launch of ALXN1840 represent a significant near-term revenue growth driver.
    2. Advancement and Potential Commercialization of MNPR-101-Lu (Therapeutic Radiopharmaceutical): Monopar's therapeutic radiopharmaceutical, MNPR-101-Lu, targets uPAR-expressing advanced or metastatic solid tumors. The FDA cleared its IND application in September 2025, allowing for a Phase 1 dosimetry and dose-escalation trial. Clinical trials are currently active and enrolling patients in Australia, with an Expanded Access Program also active in the U.S. Positive clinical data and progression to later stages could lead to partnerships or eventual market entry within the 2-3 year timeframe or shortly thereafter, generating revenue.
    3. Progression and Potential Commercialization of MNPR-101-Zr (Imaging Radiopharmaceutical): MNPR-101-Zr is an imaging agent designed to target uPAR in advanced cancer patients. This asset is currently in a first-in-human Phase 1 imaging and dosimetry clinical trial. Successful development and potential approval of this imaging agent could provide revenue through its use in cancer diagnosis and patient selection for uPAR-targeted therapies.
    4. Strategic Partnerships and Collaborations: As a clinical-stage biopharmaceutical company, Monopar's revenue growth can be significantly driven by securing and expanding strategic partnerships. Collaborations, similar to its ongoing relationship with NorthStar Medical Radioisotopes for radiopharmaceuticals, can provide non-dilutive funding, upfront payments, and milestone payments upon achieving certain development or regulatory objectives. Such partnerships could support the continued development and eventual commercialization of its pipeline assets.

    AI Analysis | Feedback

    Capital Allocation Decisions for Monopar Therapeutics (MNPR) Over the Last 3-5 Years

    Share Repurchases

    • In September 2025, Monopar Therapeutics repurchased 550,229 shares of its common stock from Tactic Pharma for $35 million, at a price of $63.6098 per share, using proceeds from a public offering.

    Share Issuance

    • In September 2025, Monopar completed an underwritten public offering of 1,034,433 shares of common stock and pre-funded warrants to purchase 960,542 shares of common stock, generating approximately $126.9 million in aggregate net proceeds before underwriting discounts and offering expenses.
    • In October 2024, the company raised approximately $19.2 million in gross proceeds through a public offering of common stock, priced at $16.25 per share.
    • During the nine months ended September 30, 2024, Monopar issued 509,061 shares of common stock under a "Capital on Demand Sales Agreement," raising $3,194,310.

    Inbound Investments

    • In October 2024, Monopar in-licensed ALXN1840 for Wilson disease from Alexion, AstraZeneca Rare Disease, a deal that included a $4 million upfront cash payment and the issuance of 387,329 shares of common stock to Alexion.
    • Monopar strengthened its financial position by raising over $55 million through various public offerings and private placements during the fourth quarter of 2024 and early 2025.

    Capital Expenditures

    • Research and development (R&D) expenses for the year ended December 31, 2023, were $5.6 million, a decrease from $7.6 million in 2022. This reduction was primarily due to lower costs associated with the Validive and camsirubicin clinical trials, partially offset by increased activity in the MNPR-101 radiopharmaceutical program.
    • R&D expenses in the second quarter of 2025 increased to $1,730,000 from $1,130,978 in the second quarter of 2024, mainly driven by higher R&D personnel expenses, including stock-based compensation.
    • The company plans to continue investing in its radiopharmaceutical pipeline, including ongoing clinical trials for MNPR-101-Zr and MNPR-101-Lu, and advancing the preclinical MNPR-101-Ac program, with current funds anticipated to support operations at least through December 31, 2027.

    Peer Outperformance in Biotechnology

    MNPR has outperformed 94% of its 374 Biotechnology peers over 5Y. Biotechnology ranks 10th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
    Share of Biotechnology constituents that MNPR has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    58%
    of 467 industry peers · 10.1% return
    3Y
    100%
    of 415 industry peers · 2850.3% return
    5Y
    94%
    of 374 industry peers · 232.9% return
    No Biotechnology peer with a comparable growth profile has beaten MNPR by more than 20pp over 5Y.
    Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is MNPR's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 6 10.8%42.7%87.6% CAH 380% · MCK 337% · COR 165%
    Managed Health Care 8 34.8%-9.4%3.1% OSCR 74% · HQY 34% · ELV 12%
    Health Care Services 20 21.2%37.1%0.2% HIMS 263% · RDNT 142% · DGX 70%
    Health Care Facilities 24 4.5%14.6%-0.9% NHC 275% · THC 264% · ENSG 135%
    Health Care Equipment 50 -1.7%-1.1%-19.3% POCI 11475% · UFPT 375% · GKOS 205%
    Health Care Supplies 12 29.6%-7.7%-38.4% LNTH 270% · HAE 52% · MMSI 21%
    Pharmaceuticals 62 -8.9%7.3%-41.9% LQDA 2284% · INDV 1094% · ETON 1051%
    Life Sciences Tools & Services 113 1.3%-10.1%-67.2% SNWV 1957% · NTRA 249% · MEDP 212%
    Health Care Technology 21 -32.6%-53.0%-78.2% SPOK 72% · HSTM 2% · VEEV -6%
    Biotechnology ← 375 -8.7%-23.0%-79.7% CELZ 1371% · DNTH 1085% · ELVN 965%
    Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

    Latest Trefis Analyses

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    GRALGRAIL5.557.1%48.3%
    SECZSecuritize2.447.0%29.8%
    BALYBallys0.834.5%-15.3%
    MRNAModerna79.229.1%574.4%
    VICRVicor13.026.6%157.3%
    QMCOQuantum0.726.3%391.2%
    OUSTOuster2.924.7%102.0%
    ARHSArhaus1.424.6%-9.1%
    BANDBandwidth2.023.1%300.1%
    VKTXViking Therapeutics4.122.7%1.1%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    XNDUXanadu Quantum Technologies1.5-32.9%-56.7%
    CGEMCullinan Therapeutics0.9-29.7%43.1%
    ALKTAlkami Technology1.5-27.9%-40.2%
    BYNDBeyond Meat4.2-27.5%-66.1%
    KDKKodiak AI0.5-25.9%-77.7%
    GENGen Digital13.0-25.5%-19.3%
    PBLSParabilis Medicines0.9-25.2%-1.3%
    CTEVClaritev0.4-24.7%-45.7%
    ACADACADIA Pharmaceuticals3.5-24.2%-22.6%
    ONTOnterris0.5-22.7%-43.6%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    SECZSecuritize2.4134.7%29.8%
    GRALGRAIL5.559.4%48.3%
    BALYBallys0.854.0%-15.3%
    MXLMaxLinear8.449.0%438.4%
    SDGRSchrodinger2.248.2%61.4%
    FEIMFrequency Electronics0.945.9%64.2%
    OKTAOkta34.445.2%125.7%
    VICRVicor13.043.0%157.3%
    ACVAACV Auctions1.842.9%30.4%
    FWDIForward Industries0.742.0%27.4%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    ADBTAdvasa0.1-97.9%-98.2%
    ALMSAlumis0.9-69.9%-27.3%
    XNDUXanadu Quantum Technologies1.5-51.5%-56.7%
    RAREUltragenyx Pharmaceutical1.5-45.2%-37.0%
    SWMRSwarmer0.3-44.0%-33.1%
    IMUXImmunic0.4-43.3%75.1%
    XENEXenon Pharmaceuticals3.7-42.1%-17.6%
    BYNDBeyond Meat4.2-41.4%-66.1%
    ALHCAlignment Healthcare1.7-40.9%-58.4%
    PRLDPrelude Therapeutics0.4-40.9%33.6%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    MNPRVRTXAPMDATTOBLSMBRVEMedian
    NameMonopar .Vertex P.Apnimed Attovia .BlossomH.Bravehea. 
    Mkt Price85.23526.1921.0917.7819.7520.6220.86
    Mkt Cap0.7133.5----67.1
    Rev LTM012,5871170000
    Op Inc LTM-224,77723-74-72-31-27
    FCF LTM-123,796-84-64-65-25-45
    FCF 3Y Avg-101,957----974
    CFO LTM-124,293-84-62-64-22-42
    CFO 3Y Avg-102,398----1,194

    Growth & Margins

    MNPRVRTXAPMDATTOBLSMBRVEMedian
    NameMonopar .Vertex P.Apnimed Attovia .BlossomH.Bravehea. 
    Rev Chg LTM-10.2%----10.2%
    Rev Chg 3Y Avg-9.8%----9.8%
    Rev Chg Q-12.5%----12.5%
    QoQ Delta Rev Chg LTM-3.0%----3.0%
    Op Inc Chg LTM-15.8%2,497.9%----1,241.1%
    Op Inc Chg 3Y Avg-48.2%792.2%----372.0%
    Op Mgn LTM-37.9%19.9%-16,551.6%--19.9%
    Op Mgn 3Y Avg-23.9%----23.9%
    QoQ Delta Op Mgn LTM--0.2%-----0.2%
    CFO/Rev LTM-34.1%-71.5%-13,695.3%---71.5%
    CFO/Rev 3Y Avg-19.6%----19.6%
    FCF/Rev LTM-30.2%-71.5%-14,194.7%---71.5%
    FCF/Rev 3Y Avg-15.7%----15.7%

    Valuation

    MNPRVRTXAPMDATTOBLSMBRVEMedian
    NameMonopar .Vertex P.Apnimed Attovia .BlossomH.Bravehea. 
    Mkt Cap0.7133.5----67.1
    P/S-10.6----10.6
    P/Op Inc-32.927.9-----2.5
    P/EBIT-32.926.5-----3.2
    P/E-40.830.3-----5.2
    P/CFO-59.831.1-----14.3
    Total Yield-2.5%3.3%----0.4%
    Dividend Yield0.0%0.0%----0.0%
    FCF Yield 3Y Avg-19.6%1.6%-----9.0%
    D/E0.00.0----0.0
    Net D/E-0.2-0.0-----0.1

    Returns

    MNPRVRTXAPMDATTOBLSMBRVEMedian
    NameMonopar .Vertex P.Apnimed Attovia .BlossomH.Bravehea. 
    1M Rtn-25.0%-3.9%-28.7%-9.1%7.0%-25.7%-17.1%
    3M Rtn-2.8%7.1%-15.6%-18.8%23.4%-30.8%-9.2%
    6M Rtn57.6%21.5%-15.6%-18.8%23.4%-30.8%2.9%
    12M Rtn10.1%37.8%-15.6%-18.8%23.4%-30.8%-2.8%
    3Y Rtn2,850.3%49.6%-15.6%-18.8%23.4%-30.8%3.9%
    1M Excs Rtn-25.9%-4.7%-29.6%-9.9%6.1%-26.6%-17.9%
    3M Excs Rtn-8.1%1.8%-20.9%-24.1%18.1%-36.1%-14.5%
    6M Excs Rtn36.7%-3.6%-35.2%-38.4%3.9%-50.4%-19.4%
    12M Excs Rtn0.0%23.1%-32.3%-35.5%6.8%-47.5%-16.1%
    3Y Excs Rtn2,703.7%-26.5%-91.5%-94.7%-52.5%-106.7%-72.0%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q3
    Period End6/30/20263/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/2023
    Filing Date8/12/20265/14/20263/27/202611/13/20258/12/20255/13/20253/31/202511/8/20248/9/20245/9/20243/28/202411/9/2023
    Key Financials Quarterly            
    Total Revenue000000000000
    Ebitda-7-5-6-4-3-3-11-2-2-2-2-2
    Operating Income-7-5-6-4-3-3-11-2-2-2-2-2
    Net Income-5-4-5-3-2-3-11-1-2-2-2-2
    EPS-0.62-0.46-0.64-0.48-0.35-0.38-2.75-0.37-0.49-0.51-0.61-0.69
    Key Financials TTM            
    Total Revenue TTM000000000000
    Ebitda TTM-22-19-17-22-19-18-16-7-7-8-9-10
    Operating Income TTM-22-19-17-22-19-18-16-7-7-8-9-10
    Net Income TTM-18-15-14-19-17-17-16-6-7-8-8-9
    Growth Rates Quarterly            
    Total Revenue Growth------------
    EBITDA Growth-105.4%-62.2%44.4%-159.9%-80.8%-86.9%-479.2%23.8%23.2%31.7%34.3%14.2%
    Operating Income Growth-105.4%-62.2%44.4%-159.9%-80.8%-86.9%-479.2%23.8%23.2%31.7%34.3%14.2%
    Net Income Growth-116.6%-48.3%52.4%-163.6%-43.0%-59.9%-502.3%33.2%22.0%32.6%37.4%18.6%
    Margins Quarterly            
    EBITDA Margin------------
    Operating Income Margin------------
    Net Income Margin------------
    Cash & Debt            
    Total Cash13413714014453556067978
    Total Debt000000000000
    Net Debt / (Cash)-134-137-140-144-53-55-60-6-7-9-7-8
    Cash Flows Quarterly            
    FCF from Operations-3-3-3-2-1-6-2-1-2-2-2-2
    Cash Flows TTM            
    FCF from Operations TTM-12-10-12-11-10-10-6-6-7-7-8-8
    Returns to Shareholders Quarterly            
    Dividends000000000000
    Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
    Return on Invested Capital (ROIC) Quarterly            
    ROIC-27.9%-22.9%-28.3%-19.9%-16.2%-16.6%-62.7%-9.9%-11.4%-11.4%-13.1%-14.6%
    Return on Invested Capital (ROIC) TTM            
    ROIC TTM-23.2%-20.5%-19.2%-26.3%-23.9%-22.8%-22.9%-11.0%-12.0%-13.3%-15.1%-17.4%

    Segment Financials

    Assets by Segment
    $ Mil20252024202320222021
    Development of clinical and preclinical product candidates1416071321
    Total1416071321


    Price Behavior

    Price Behavior
    Market Price$85.23 
    Market Cap ($ Bil)0.7 
    First Trading Date12/19/2019 
    Distance from 52W High-31.2% 
       50 Days200 Days
    DMA Price$110.08$76.13
    DMA Trendupup
    Distance from DMA-22.6%12.0%
     3M1YR
    Volatility59.8%68.1%
    Downside Capture237.16180.13
    Upside Capture159.98157.12
    Correlation (SPY)41.8%28.6%
    MNPR Betas & Captures as of 8/31/2026

     1M2M3M6M1Y3Y
    Beta1.952.230.761.441.471.66
    Up Beta2.322.522.662.822.600.66
    Down Beta6.812.83-0.14-0.090.841.15
    Up Capture124%259%188%263%310%5285%
    Bmk +ve Days10213268138427
    Stock +ve Days13233666131367
    Down Capture122%137%-108%73%76%108%
    Bmk -ve Days11213259113324
    Stock -ve Days8192860118373

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with MNPR
    MNPR16.8%68.2%0.50-
    Sector ETF (XLV)26.9%16.2%1.2817.4%
    Equity (SPY)17.7%13.0%0.9828.2%
    Gold (GLD)14.7%29.3%0.4615.5%
    Commodities (DBC)46.8%20.7%1.75-15.0%
    Real Estate (VNQ)4.5%13.6%0.0712.6%
    Bitcoin (BTCUSD)-25.5%44.8%-0.5310.5%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with MNPR
    MNPR25.5%295.8%0.56-
    Sector ETF (XLV)6.8%15.2%0.261.3%
    Equity (SPY)13.3%17.2%0.594.8%
    Gold (GLD)19.2%18.8%0.833.9%
    Commodities (DBC)11.2%19.5%0.45-0.9%
    Real Estate (VNQ)0.9%18.9%-0.062.5%
    Bitcoin (BTCUSD)12.3%52.6%0.413.4%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with MNPR
    MNPR-4.8%259.6%0.43-
    Sector ETF (XLV)10.9%16.7%0.533.2%
    Equity (SPY)15.5%17.9%0.735.6%
    Gold (GLD)12.1%16.4%0.613.6%
    Commodities (DBC)8.7%18.1%0.390.2%
    Real Estate (VNQ)4.8%20.7%0.193.9%
    Bitcoin (BTCUSD)63.9%66.2%1.043.2%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date9152026
    Short Interest: Shares Quantity0.8 Mil
    Short Interest: % Change Since 8312026-1.0%
    Average Daily Volume0.1 Mil
    Days-to-Cover Short Interest7.2 days
    Basic Shares Quantity8.5 Mil
    Short % of Basic Shares9.9%

    Earnings Returns History

    Updated 9/15/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/12/20260.4%4.0%-3.9%
    5/14/2026-2.8%2.8%0.8%
    3/27/2026-1.5%-0.8%0.7%
    11/13/20255.4%0.5%-9.0%
    8/12/202514.6%9.3%36.9%
    5/13/2025-3.6%5.1%-1.3%
    11/8/20247.3%15.9%41.6%
    8/9/2024-19.6%-13.8%-12.7%
    ...
    SUMMARY STATS   
    # Positive998
    # Negative121213
    Median Positive1.2%5.1%14.1%
    Median Negative-4.4%-13.5%-10.2%
    Max Positive14.6%15.9%41.6%
    Max Negative-24.8%-45.8%-54.9%
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/12/20260.4%4.0%-3.9%
    5/14/2026-2.8%2.8%0.8%
    3/27/2026-1.5%-0.8%0.7%
    11/13/20255.4%0.5%-9.0%
    8/12/202514.6%9.3%36.9%
    5/13/2025-3.6%5.1%-1.3%
    11/8/20247.3%15.9%41.6%
    8/9/2024-19.6%-13.8%-12.7%
    5/9/2024-5.2%-20.3%8.1%
    11/9/2023-3.0%-21.9%-6.6%
    8/10/20233.2%-13.5%-20.4%
    5/11/2023-6.6%-13.5%-6.0%
    3/23/20230.6%-45.8%-54.9%
    11/10/2022-24.8%-37.1%-42.4%
    8/11/20220.3%-1.9%-4.7%
    5/12/2022-8.0%9.5%14.4%
    3/24/2022-1.1%2.3%-10.2%
    11/12/2021-0.2%-3.0%-20.0%
    8/12/20211.2%-0.6%13.7%
    5/13/20211.2%8.7%19.4%
    3/25/2021-6.4%-7.7%-12.8%
    SUMMARY STATS   
    # Positive998
    # Negative121213
    Median Positive1.2%5.1%14.1%
    Median Negative-4.4%-13.5%-10.2%
    Max Positive14.6%15.9%41.6%
    Max Negative-24.8%-45.8%-54.9%

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/12/202610-Q
    03/31/202605/14/202610-Q
    12/31/202503/27/202610-K
    09/30/202511/13/202510-Q
    06/30/202508/12/202510-Q
    03/31/202505/13/202510-Q
    12/31/202403/31/202510-K
    09/30/202411/08/202410-Q
    06/30/202408/09/202410-Q
    03/31/202405/09/202410-Q
    12/31/202303/28/202410-K
    09/30/202311/09/202310-Q
    06/30/202308/10/202310-Q
    03/31/202305/11/202310-Q
    12/31/202203/23/202310-K
    09/30/202211/10/202210-Q
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/12/202610-Q
    03/31/202605/14/202610-Q
    12/31/202503/27/202610-K
    09/30/202511/13/202510-Q
    06/30/202508/12/202510-Q
    03/31/202505/13/202510-Q
    12/31/202403/31/202510-K
    09/30/202411/08/202410-Q
    06/30/202408/09/202410-Q
    03/31/202405/09/202410-Q
    12/31/202303/28/202410-K
    09/30/202311/09/202310-Q
    06/30/202308/10/202310-Q
    03/31/202305/11/202310-Q
    12/31/202203/23/202310-K
    09/30/202211/10/202210-Q
    06/30/202208/11/202210-Q
    03/31/202205/12/202210-Q
    12/31/202103/24/202210-K
    09/30/202111/12/202110-Q
    06/30/202108/12/202110-Q
    03/31/202105/13/202110-Q
    12/31/202003/25/202110-K
    09/30/202011/12/202010-Q
    06/30/202008/06/202010-Q
    03/31/202005/07/202010-Q
    12/31/201903/27/202010-K
    09/30/201912/19/2019424B4

    Insider Activity

    Updated 8/28/2026
    Expand for More
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Rioux, Patrice DirectSell8272026111.261111563,532Form
    2Tsuchimoto, Kim R DirectSell8272026111.394,090455,567823,807Form
    3Anderson, Raymond DirectSell8272026111.773,142351,1892,654,708Form
    4Vu, Quan AnhChief Financial OfficerDirectBuy1229202569.951,500104,925104,925Form
    5Klausner, Arthur J DirectSell1219202567.155,121343,889588,392Form
     Collapse to Preview
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Rioux, Patrice DirectSell8272026111.261111563,532Form
    2Tsuchimoto, Kim R DirectSell8272026111.394,090455,567823,807Form
    3Anderson, Raymond DirectSell8272026111.773,142351,1892,654,708Form
    4Vu, Quan AnhChief Financial OfficerDirectBuy1229202569.951,500104,925104,925Form
    5Klausner, Arthur J DirectSell1219202567.155,121343,889588,392Form
    6Tactic, Pharma LlcChief Executive OfficerDirectSell926202563.61550,22934,999,95717,303,519Form

    Investor Activity (13F)

    Updated Sep 26, 2026
    13F holdings as of Mar 31, 2026 (Q1 2026)

    Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Saturn V Capital Management LP$18.9 Mil3.4%21ADD +6.1%13F
    TCG Crossover Management, LLC$7.2 Mil0.2%49TRIM -6.9%13F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Saturn V Capital Management LP$18.9 Mil3.4%21ADD +6.1%13F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    TCG Crossover Management, LLC$7.2 Mil0.2%49TRIM -6.9%13F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Saturn V Capital Management LP$18.9 Mil3.4%21ADD +6.1%13F
    TCG Crossover Management, LLC$7.2 Mil0.2%49TRIM -6.9%13F

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 9/25/2026